Clinical Research Directory

Patients * Age \<65 years (not to have influence on functioning of desaturase enzymes that decline with older ages). * Neoplastic pathology: primary invasive breast cancer or ductal in situ (DCIS) newly diagnosed, in the pre-operative phase and which has not already undergone chemo- or radiotherapy. * Absence of serious intestinal and hepatic pathologies, diabetes, both insulin-dependent and in hypoglycaemic treatment or other pancreatic affection, thyroid affections in pharmacological treatment. * Absence of supplementation with omega-3 based supplements for at least 6 months. * Homogeneous distribution by BMI (1:1 ratio subjects with BMI≥25 and BMI\<25, respectively). * Informed consent to participate in the study. controls * Age \<65 years; * Not be affected by cancer; * BMI \<25kg/m2; * Informed consent to participate in the study Exclusion Criteria: patients * Age ≥65 years (would affect the functioning of desaturase enzymes that decline with older age). * Invasive primary breast cancer or ductal in situ (DCIS) previously treated with chemo- or radiotherapy. * Metastasis at diagnosis. * Presence of serious intestinal and hepatic pathologies. * Presence of diabetes, both insulin-dependent and in hypoglycaemic treatment or other pancreatic disease, thyroid disease in pharmacological treatment. * Supplementation with omega-3 based supplements for at least 6 months. * Failure to sign the informed consent to participate in the study. controls * Age ≥65 years; * Suffering from tumor pathology; * BMI ≥25kg/m2; * Refusal to sign informed consent to participate in the study.